Bearing Point Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.55M Sell
2,775
-2
-0.1% -$2.03K 0.4% 66
2025
Q4
$2.98M Buy
2,777
+103
+4% +$98.5K 0.47% 64
2025
Q3
$2.04M Sell
2,674
-253
-9% -$188K 0.35% 67
2025
Q2
$2.28M Buy
2,927
+204
+7% +$159K 0.42% 64
2025
Q1
$2.25M Buy
2,723
+237
+10% +$197K 0.48% 63
2024
Q4
$1.92M Buy
+2,486
New +$2.06M 0.4% 65

Other funds holding LLY

Bearing Point Capital's LLY Position: Q1 2026 in Review

Bearing Point Capital reduced its Eli Lilly (LLY) stake by 0.07% in Q1 2026, selling an estimated $2.03K and leaving 2,775 shares worth $2.55M. The position accounts for 0.4% of the portfolio, ranked #66.

Bearing Point Capital first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.98M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bearing Point Capital held 2,775 shares of Eli Lilly worth $2.55M as of Q1 2026.
  • Bearing Point Capital sold 2 Eli Lilly shares in Q1 2026, an estimated $2.03K.
  • Eli Lilly made up 0.4% of Bearing Point Capital's portfolio in Q1 2026, its #66 holding.
  • Bearing Point Capital first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Bearing Point Capital's Eli Lilly position peaked at $2.98M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bearing Point Capital's 13F filing for Q1 2026, filed 7 May 2026.